FDA Implements Quarterly System for VAT-Exempt Pharmaceutical Products List
The Food and Drug Administration (FDA) has announced a significant change in how it manages the highly anticipated list of value-added tax (VAT)-exempt pharmaceutical products. The health regulatory agency will now publish updates to this crucial list on a quarterly basis, providing more frequent adjustments to the medications that qualify for tax exemption.
Regular Quarterly Updates Established
In Advisory 2026-0382, the FDA clarified that updates to the List of VAT-Exempt Pharmaceutical Products for Human Use will be incorporated through regular quarterly updates. This systematic approach replaces previous irregular publication schedules, creating a more predictable framework for pharmaceutical companies, healthcare providers, and patients awaiting the list.
The agency issued this advisory to inform the public about the new quarterly schedule, addressing widespread anticipation for the VAT-exempt products list that directly impacts medication affordability for millions of Filipinos.
New Request Process for Pharmaceutical Companies
Under the new system, the FDA will now accept requests from marketing authorization holders (MAHs) for inclusion, delisting, or correction of entries in the pharmaceutical products list. This represents a more structured approach to managing the medications that receive VAT exemption status.
Specifically, requests concerning medicines for diabetes, hypertension, cancer, high cholesterol, mental illnesses, tuberculosis, or kidney diseases must be submitted to the Center for Drug Regulation and Research (CDRR). These categories represent some of the most critical healthcare needs in the Philippines and are prioritized in the VAT exemption program.
Comprehensive Documentation Requirements
When submitting requests, MAHs must provide extensive documentation to support their applications. The FDA requires:
- Generic name and brand name of the pharmaceutical product
- Dosage strength and dosage form specifications
- Route of administration details
- Certificate of Product Registration (CPR) number
- Specific medical indications for the medication
Additionally, MAHs must specify the type of request being made, identify the particular list of concern, and provide other relevant details including justification for the request. This comprehensive documentation ensures that only appropriate medications receive VAT exemption status under the established guidelines.
Legal Framework and Healthcare Objectives
The VAT exemption for pharmaceutical products operates under the Corporate Recovery and Tax Incentives for Enterprises (Create) Act, which grants tax exemptions to specific health products deemed essential for public health. This legislative framework provides the legal basis for removing value-added tax from critical medications.
This initiative aligns with National Government efforts to ensure accessible and affordable healthcare for all Filipinos. By reducing the tax burden on essential medications, the government aims to lower out-of-pocket expenses for patients managing chronic and serious medical conditions, potentially improving medication adherence and health outcomes nationwide.
The quarterly update system represents a more responsive approach to pharmaceutical regulation, allowing the FDA to regularly adjust the VAT-exempt list based on emerging healthcare needs, new medication approvals, and changing treatment paradigms while maintaining the program's integrity and alignment with national health objectives.
